UNITED STATES SECURITIES AND EXCHANGE COMMISSION 23 January 2015

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

SPECTRUM PHARMACEUTICALS INC.

File No. 1-35006 -- CF# 31925

SPECTRUM PHARMACEUTICALS INC. submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on November 9, 2012.

Based on representations by SPECTRUM PHARMACEUTICALS INC. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.14 through December 31, 2019 Exhibit 10.15 through December 31, 2019

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary